Nearly 700,000 US hospitalizations and 110,000 deaths prevented from the Pfizer-BioNTech COVID-19 vaccine
- Details
- Category: Business
The profound health and economic impact of the Pfizer-BioNTech vaccine during its first year of rollout in the US is described in detail in a new study in the peer-reviewed Journal of Medical Economics.
It is estimated that in 2021 the vaccine, the most widely used against COVID-19 in the US, prevented 8.7 million symptomatic cases of the virus, as well as 690,000 hospitalizations and more than 110,000 deaths.
Pfizer and BioNTech provide update on COVID-19 vaccine supply agreement with European Commission
- Details
- Category: Business
Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced they have reached an agreement with the European Commission (EC) to amend their originally agreed contractual delivery schedules for the Pfizer-BioNTech COVID-19 Vaccine.
Roche pledges to extend commitment to the World Federation of Hemophilia Humanitarian Aid Program to 2028
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) has extended its commitment to the World Federation of Hemophilia (WFH) Humanitarian Aid Program until the end of 2028. Roche’s prophylactic treatment will be provided to the WFH Humanitarian Aid Program to continue to treat as many as 1,000 people with haemophilia A in locations where there is little to no access to treatment.
Pfizer to acquire Biohaven Pharmaceuticals
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) and Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) have entered into a definitive agreement under which Pfizer will acquire Biohaven, the maker of NURTEC® ODT, an innovative dual-acting migraine therapy approved for both acute treatment and episodic prevention of migraine in adults.
Foundation S: Sanofi's new philanthropic spearhead
- Details
- Category: Sanofi
Sanofi today launches Foundation S - The Sanofi Collective, its philanthropic endowment fund aiming to create healthier futures for generations. Using donations, partnerships and collective action, Foundation S will focus on three critical areas: childhood cancer, the health of communities most vulnerable to the effects of climate change and pollution, and access to lifesaving medicines and vaccines.
Pfizer shares top-line results from Phase 2/3 EPIC-PEP study of PAXLOVID™ for post-exposure prophylactic use
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) shared top-line results from the Phase 2/3 EPIC-PEP (Evaluation of Protease Inhibition for COVID-19 in Post-Exposure Prophylaxis) study evaluating PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) for post-exposure prophylactic use. In this trial, compared to placebo, Pfizer observed risk reductions of 32% and 37% in adults who received PAXLOVID for five and ten days, respectively, to prevent infection.
SK bioscience and GSK's adjuvanted COVID-19 vaccine candidate meets coprimary objectives in a phase III study
- Details
- Category: GlaxoSmithKline
SK bioscience and GSK announced submission of a biologics license application for SKYCovione™ a recombinant protein-based COVID-19 vaccine candidate adjuvanted with GSK’s pandemic adjuvant, to the Korean Ministry of Food and Drug Safety (KMFDS) following positive Phase III clinical data.
More Pharma News ...
- Pfizer and Biohaven's VYDURA® (rimegepant) granted first ever marketing authorization by European Commission for both acute treatment of migraine and prophylaxis of episodic migraine
- Novartis provides more than USD 25 million in medical aid to patients in Ukraine and bordering countries
- Evusheld significantly protected against symptomatic COVID-19 for at least six months in PROVENT Phase III trial in high-risk populations
- GSK reaches agreement to acquire late-stage biopharmaceutical company Sierra Oncology for $1.9bn
- Sanofi launches first-in-pharma Diversity, Equity & Inclusion Board
- Pfizer to acquire ReViral and its respiratory syncytial virus therapeutic candidates
- Novartis announces new organizational structure